Personalized medicine in lipid-modifying therapy

Brian Tomlinson, Chen Hsiu Lin, Paul Chan, Christopher W.K. Lam

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


The choice of lipid-modifying treatment is largely based on the absolute level of cardiovascular risk and baseline lipid profile. Statins are the first-line treatment for most patients requiring reduction of low-density-lipoprotein cholesterol (LDL-C) and ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitors can be added to reach LDL-C targets. Statins have some adverse effects that are somewhat predictable based on phenotypic and genetic factors. Fibrates or omega-3 fatty acids can be added if triglyceride levels remain elevated. The RNA-Targeted therapeutics in development offer the possibility of selective liver targeting for specific lipoproteins such as lipoprotein(a) and long-Term reduction of LDL-C with infrequent administration of a small-interfering RNA may help to overcome the problem of adherence to therapy.

Original languageEnglish
Pages (from-to)185-203
Number of pages19
JournalPersonalized Medicine
Issue number3
Publication statusPublished - Mar 2021


  • cardiovascular risk
  • ezetimibe
  • fibrates
  • lipoprotein(a)
  • low-density-lipoprotein cholesterol
  • omega-3 fatty acids
  • proprotein convertase subtilisin/kexin type 9 inhibitors
  • small-interfering RNA
  • statins
  • triglycerides

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Personalized medicine in lipid-modifying therapy'. Together they form a unique fingerprint.

Cite this